Hummingbird Bioscience
PrivateLast Round
Series C
May 18, 2021
Total Funding Raised
$182.1M
Company Overview
Hummingbird Bioscience operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was a Series C round in May 2021.
Hummingbird Bioscience is a biotechnology company that develops innovative therapeutic antibody-based drugs aimed at addressing the significant unmet needs of oncology and immuno-oncology patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hummingbird Bioscience Comparables
Compare Hummingbird Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera Biologics Inc. | 81% | |
| Biolojic Design | 81% | |
| BenevolentAI | 79% |
For institutional investors. Book with your work email.
Hummingbird Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 18, 2021 | ||||
| Series B Extension | May 10, 2020 | ||||
| Series B | Dec 4, 2019 | ||||
| Series A Extension | Jul 10, 2019 | ||||
| Grant | Feb 21, 2019 | ||||
Series A | May 3, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hummingbird Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heritas Capital Management | Series B, Series C, Series B Extension, Series A Extension |
| Cancer Prevention & Research Institute of Texas | Grant |
| Frazier Healthcare Partners | Series C |
| SEEDS Capital | Series B, Series C, Series B Extension, Series A Extension |
| Mirae Asset | Series B, Series C |
| Octagon Capital Advisors | Series C |
| Ally Bridge Group | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 15, 2025
Clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity.
- May 18, 2021
$125M round led by Novo Holdings.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 28, 2026
Hummingbird Bioscience Pte Ltd. is working with LynxKite to build an explainable Toxicity Knowledge Graph using Nemotron 3.5 Lightning and NeMo Retriever to accelerate drug discovery in Singapore.
- partners_withSep 28, 2026
On Sep 28th '26, Hummingbird Bioscience Pte Ltd. works with LynxKite Technologies Pte Ltd in Singapore to build an explainable Toxicity Knowledge Graph using Nemotron 3.5 Lightning and NeMo Retriever, intended to accelerate drug discovery.
- hiresSep 15, 2026
Hummingbird Bioscience Pte Ltd. appoints Dr. James Garner as President in Singapore on Sep 15th '26, and he is set to join its leadership team alongside co-founder and CEO Piers Ingram.
- hiresSep 15, 2026
Hummingbird Bioscience Pte Ltd. appoints Dr. James Garner as President in Singapore on Sep 15th '26, joining its leadership team and working alongside co-founder and CEO Piers Ingram, PhD.
For institutional investors. Book with your work email.
Hummingbird Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hummingbird Bioscience's valuation, stock price, and market status.
Is Hummingbird Bioscience a public or private company?
Hummingbird Bioscience is a private company.
What is the current stock price of Hummingbird Bioscience?
Hummingbird Bioscience is a private company, so its shares have no public market price. Caplight tracks Hummingbird Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hummingbird Bioscience worth (valuation)?
Valuation information for Hummingbird Bioscience is not publicly available.
Can I buy Hummingbird Bioscience stock?
Hummingbird Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hummingbird Bioscience's last funding round?
Hummingbird Bioscience's most recent funding round was Series C on May 18, 2021.
Who are the main investors in Hummingbird Bioscience?
Key investors in Hummingbird Bioscience include Heritas Capital Management, Cancer Prevention & Research Institute of Texas, SEEDS Capital, Mirae Asset, SK Inc..
Will Hummingbird Bioscience IPO soon?
No public IPO plans have been announced for Hummingbird Bioscience.
How can I track Hummingbird Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Hummingbird Bioscience's shares on secondary markets.